These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 34375027)

  • 1. Potent Tau Aggregation Inhibitor D-Peptides Selected against Tau-Repeat 2 Using Mirror Image Phage Display.
    Malhis M; Kaniyappan S; Aillaud I; Chandupatla RR; Ramirez LM; Zweckstetter M; Horn AHC; Mandelkow E; Sticht H; Funke SA
    Chembiochem; 2021 Nov; 22(21):3049-3059. PubMed ID: 34375027
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mirror-Image Phage Display for the Selection of D-Amino Acid Peptide Ligands as Potential Therapeutics.
    Malhis M; Funke SA
    Curr Protoc; 2024 Feb; 4(2):e957. PubMed ID: 38372457
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selection of a d-Enantiomeric Peptide Specifically Binding to PHF6 for Inhibiting Tau Aggregation in Transgenic Mice.
    Zhang X; Zhang X; Zhong M; Zhao P; Guo C; Li Y; Wang T; Gao H
    ACS Chem Neurosci; 2020 Dec; 11(24):4240-4253. PubMed ID: 33284003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selection and Characterization of Tau Binding ᴅ-Enantiomeric Peptides with Potential for Therapy of Alzheimer Disease.
    Dammers C; Yolcu D; Kukuk L; Willbold D; Pickhardt M; Mandelkow E; Horn AH; Sticht H; Malhis MN; Will N; Schuster J; Funke SA
    PLoS One; 2016; 11(12):e0167432. PubMed ID: 28006031
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel D-amino acid peptide with therapeutic potential (ISAD1) inhibits aggregation of neurotoxic disease-relevant mutant Tau and prevents Tau toxicity in vitro.
    Aillaud I; Kaniyappan S; Chandupatla RR; Ramirez LM; Alkhashrom S; Eichler J; Horn AHC; Zweckstetter M; Mandelkow E; Sticht H; Funke SA
    Alzheimers Res Ther; 2022 Jan; 14(1):15. PubMed ID: 35063014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of tau amyloid formation and disruption of its preformed fibrils by Naphthoquinone-Dopamine hybrid.
    Paul A; Viswanathan GK; Huber A; Arad E; Engel H; Jelinek R; Gazit E; Segal D
    FEBS J; 2021 Jul; 288(14):4267-4290. PubMed ID: 33523571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Purpurin modulates Tau-derived VQIVYK fibrillization and ameliorates Alzheimer's disease-like symptoms in animal model.
    Viswanathan GK; Shwartz D; Losev Y; Arad E; Shemesh C; Pichinuk E; Engel H; Raveh A; Jelinek R; Cooper I; Gosselet F; Gazit E; Segal D
    Cell Mol Life Sci; 2020 Jul; 77(14):2795-2813. PubMed ID: 31562564
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deciphering the Inhibitory Mechanism of Naphthoquinone-Dopamine on the Aggregation of Tau Core Fragments PHF6* and PHF6.
    Zou Y; Qi B; Tan J; Guan L; Zhang Q; Sun Y; Huang F
    ACS Chem Neurosci; 2023 Sep; 14(17):3265-3277. PubMed ID: 37585669
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of Aggregation Mechanism of Acetylated PHF6* and PHF6 Tau Peptides Based on Molecular Dynamics Simulations and Markov State Modeling.
    Shah SJA; Zhang Q; Guo J; Liu H; Liu H; Villà-Freixa J
    ACS Chem Neurosci; 2023 Nov; 14(21):3959-3971. PubMed ID: 37830541
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Integrating in vitro and in silico approaches to evaluate the "dual functionality" of palmatine chloride in inhibiting and disassembling Tau-derived VQIVYK peptide fibrils.
    Haj E; Losev Y; Guru KrishnaKumar V; Pichinuk E; Engel H; Raveh A; Gazit E; Segal D
    Biochim Biophys Acta Gen Subj; 2018 Jul; 1862(7):1565-1575. PubMed ID: 29634991
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of two VQIXXK motifs for tau fibrillization in vitro.
    Li W; Lee VM
    Biochemistry; 2006 Dec; 45(51):15692-701. PubMed ID: 17176091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stabilization of Monomeric Tau Protein by All D-Enantiomeric Peptide Ligands as Therapeutic Strategy for Alzheimer's Disease and Other Tauopathies.
    Altendorf T; Gering I; Santiago-Schübel B; Aghabashlou Saisan S; Tamgüney G; Tusche M; Honold D; Schemmert S; Hoyer W; Mohrlüder J; Willbold D
    Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768484
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disclosing the Mechanism of Spontaneous Aggregation and Template-Induced Misfolding of the Key Hexapeptide (PHF6) of Tau Protein Based on Molecular Dynamics Simulation.
    Liu H; Zhong H; Liu X; Zhou S; Tan S; Liu H; Yao X
    ACS Chem Neurosci; 2019 Dec; 10(12):4810-4823. PubMed ID: 31661961
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Primary Fibril Nucleation of Aggregation Prone Tau Fragments PHF6 and PHF6.
    Smit FX; Luiken JA; Bolhuis PG
    J Phys Chem B; 2017 Apr; 121(15):3250-3261. PubMed ID: 27776213
    [TBL] [Abstract][Full Text] [Related]  

  • 15. On the Tracks of the Aggregation Mechanism of the PHF6 Peptide from Tau Protein: Molecular Dynamics, Energy, and Interaction Network Investigations.
    Fagnen C; Giovannini J; Catto M; Voisin-Chiret AS; Sopkova-de Oliveira Santos J
    ACS Chem Neurosci; 2022 Oct; 13(19):2874-2887. PubMed ID: 36153969
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of All-Atom Molecular Mechanics Force Fields on Amyloid Peptide Assembly: The Case of PHF6 Peptide of Tau Protein.
    Man VH; He X; Gao J; Wang J
    J Chem Theory Comput; 2021 Oct; 17(10):6458-6471. PubMed ID: 34491058
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Terminal Capping of an Amyloidogenic Tau Fragment Modulates Its Fibrillation Propensity.
    Arya S; Ganguly P; Arsiccio A; Claud SL; Trapp B; Schonfeld GE; Liu X; Lazar Cantrell K; Shea JE; Bowers MT
    J Phys Chem B; 2020 Oct; 124(40):8772-8783. PubMed ID: 32816481
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atomistic Insights into the Inhibitory Mechanism of Tyrosine Phosphorylation against the Aggregation of Human Tau Fragment PHF6.
    Zou Y; Guan L; Tan J; Qi B; Wang Y; Zhang Q; Sun Y
    J Phys Chem B; 2023 Jan; 127(1):335-345. PubMed ID: 36594671
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disruption of PHF6 Peptide Aggregation from Tau Protein: Mechanisms of Palmatine Chloride in Preventing Early PHF6 Aggregation.
    Fagnen C; Giovannini J; Vignol T; Since M; Catto M; Voisin-Chiret AS; Sopkova-de Oliveira Santos J
    ACS Chem Neurosci; 2024 Nov; 15(21):3981-3990. PubMed ID: 39404232
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel peptide-based tau aggregation inhibitor as a potential therapeutic for Alzheimer's disease and other tauopathies.
    Aggidis A; Devitt G; Zhang Y; Chatterjee S; Townsend D; Fullwood NJ; Ortega ER; Tarutani A; Hasegawa M; Cooper A; Williamson P; Mendoza-Oliva A; Diamond MI; Mudher A; Allsop D
    Alzheimers Dement; 2024 Nov; 20(11):7788-7804. PubMed ID: 39360630
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.